Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan.

Slides:



Advertisements
Similar presentations
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Advertisements

Chicken Soup for the Busy Coordinator September 2009.
Adverse Events and Serious Adverse Events
Safety Reporting IN Clinical Trials
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
UNANTICIPATED PROBLEMS INVOLVING RISKS TO SUBJECTS OR OTHERS & INCIDENTS OF NON-COMPLIANCE ( AKA PROTOCOL DEVIATIONS ) TRACY RIGHTMER, JD, CIP COMPLIANCE.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
Unanticipated Problems Involving Risk to Subjects or Others (UPIRSO) Roy R. Estrada, PhD, PA-C, CIP Associate Director IRB UTHSCSA.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Capturing and Reporting Adverse Events in Clinical Research
Director, Investigator Support & Integration Services, OCTRI
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Vanderbilt Human Research Protections Program
Is this Research? Exempt? Expedited?
DO THE CODES APPLY TO MY RESEARCH?
Overview of Good Clinical Practices (GCPs)
Defining Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
International Human Subject Research Legal and Ethical Considerations for Investigators Theresa J. Colecchia, Esq. Associate General Counsel May 8, 2006.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
AAHRPP Accreditation Karen L. Smarr, PhD Human Research Compliance Officer Truman VA Hospital, Columbia, MO Cincinnati, OH March 19, 2007.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
New Adverse Event Reporting Policy Effective September 1, 2007.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
Understanding Unanticipated Problems (UPs) Elizabeth Ness, RN, MS Director, Staff Development Office of the Clinical Director Center for Cancer Research,
1 Unanticipated problems Melody Lin, Ph.D. December,
$100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 Terms Clinical Trial Facts.
Investigational Devices and Humanitarian Use Devices June 2007.
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Houston, We have a Problem: When and How to Report Problems to the IRB.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.
Main Line Hospitals Institutional Review Board Unanticipated Problems Anne Marie Hobson, BSN, JD, ORA Director Theresa Greaves, ORA Manager.
Good Clinical Practice (GCP) and Monitoring Practices
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
Conditional IRB Approval
Reportable Events Emory IRB 9/11/2014.
Clinicaltrials.gov Update
IRB reporting updates.
What is a Data and Safety Monitoring Plan and how do I get one?
Reportable Events & Other IRB Updates February 2017
Adverse Event Reporting: Trials and Tribulations
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
This takes approximately 5 minutes or less from start to finish
Jeffrey M. Cohen, Ph.D. Associate Dean,
Exploring 45 CFR , Criteria for IRB Approval of Research
Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)
HHS Reporting Requirements and Adverse Events
Event Reporting in Human Subjects Research
Policy on Prompt Reporting
Protocol Approval Criteria
Research with Human Subjects
Institutional Review Board
Presentation transcript:

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan Bussara Sukpanichnant, CIP USAMD-AFRIMS 1

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Why I need to know about Unanticipated Problems? Unanticipated Problem Involving Risks to Subjects or Others (UPIRTSO) reporting requirements apply to all nonexempt human subjects research that is conducted, supported, or funded- by the U.S. Department of Health and Human Services (HHS) (e.g. NIH, CDC, FDA) by other institutes adopting the Common Rule and covered by a Federal-wide Assurances (FWA) (e.g. All U.S. Department of Defense Components) orFederal-wide Assurances covered by an FWA, regardless of funding source (e.g. Most universities that accept U.S. Federal funding, even just in part). Guidance on Reporting Incidents to OHRP 2

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Problem Involving Risks to Subjects or Others (UPIRTSO) Any incident, experience, or outcome that meets all of these: UNEXPECTED in terms of nature, severity, or frequency RELATED or possibly related to participation in the research Places subjects or others at A GREATER RISK OF HARM (including physical, psychological, economic, or social harm) than was previously known or recognized OHRP Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Event 3

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Example of an UPIRTSO A subject who was a control in a malaria challenge trial (so, we knew he was going to get malaria) became incarcerated at day 7. We had to walk thru the 3 steps of whether this was an UP. – Unexpected- YES – Related to participation in the research-YES – Places subjects at a greater risk of harm-YES We had to work with the prison health clinic to get him treated. 4

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS UP vs. UPIRTSO An Unanticipated Problem (UP) is an unexpected problem/adverse event/minor deviation- that does not mean that it caused or could have caused harm. (These are reported in the Continuing Review Report.) An Unanticipated Problem Involving Risks to Subjects or Others (UPIRTSO) is what we are about speaking. It is hereinafter referred to as an unanticipated problem or UP. 5

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Adverse Events (AE) An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. ICH GCP E6 6

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Adverse Events (AE) The HHS regulations at 45 CFR part 46 do not use the term adverse event but it is described in the ICH GCP E6 and recommended when generating clinical trial data that are intended to be submitted to regulatory authorities (e.g. US FDA). 7

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS UPs vs AEs Adverse Events that are NOT Unanticipated Problems Unanticipated Problems that are NOT Adverse Events that are Unanticipated Problems Adverse Events Unanticipated Problems C = A = B = 8

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Example an AE that is NOT an UP (Area A) A subject had a broken right arm involving a car accident on the way to work which he was not a driver. – Unexpected- YES – Related to participation in the research-NO – Places subjects at a greater risk of harm-YES 9

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Example an AE that is an UP (Area B) In a study in Kenya- sickle cell drug in children a child died from an aneurism (she bled to death) and it was thought that the study drug contributed. The IRB had to walk thru the 3 steps of whether this drug "caused" the death... and was thus a UP. – Unexpected- YES – Related to participation in the research-YES – Places subjects at a greater risk of harm-YES 10

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Examples of UPs that are not AEs (Area C) Collected individually identifiable sensitive information of subjects are stored on a laptop computer without encryption, and the laptop computer is stolen from the PI. A subject receives a dose of an experimental agent that is 10-times higher than the dose dictated by the IRB- approved protocol. However, the subject experienced no detectable harm or AE. After several subjects are enrolled and receive an investigational biologic product derived from human sera. It was found that the product was obtained from donors who were not appropriately screened and tested for several potential viral contaminants e.g. hepatitis B virus. 11

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS UPs Reporting to IRB Investigators must promptly report the IRB when there is an AE or series of AEs which are determined to meet the criteria for an UP (Area B) OR an UP not related to adverse events (Area C). (45 CFR (b)(5)) 12

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Information in UP report to IRB Title and number of the research project Name of the PI Description of the event Explanation of the basis for determining that the adverse event represents an unanticipated problem Description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP OHRP Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Event 13

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS IRB Review and Action When reviewing a report of an unanticipated problem, the IRB should consider whether risks to subjects are still minimized and reasonable in relation to the anticipated benefits, any action and/or a protocol amendment is required? The IRB or appropriate institutional official, is responsible for reporting UPs to the supporting HHS agency head (e.g. NIH) and OHRP. In addition it may need to report to higher level office as required by the institute policy. Guidance on Reporting Incidents to OHRP, 45 CRF (b) 14

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Conflict with ICH GCP? All SAEs should be reported immediately to the SPONSOR. UNEXPECTED SERIOUS ADVERSE DRUG REACTIONS (ADR = related AEs) should be reported to the regulatory authority(ies) and the IRB/IEC. ICH GCP

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Take Home Messages UP Reports are required for human subjects research that is conducted or supported by most of US government institutions and other institutes covered by FWAs. All UPs must be reported promptly per 45 CRF 46. Not all AEs are UPs. (see definitions) In addition to UPs, AE and SAE must be reported per ICH GCP E6 and local requirements where applicable. 16

Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Disclaimer The opinions expressed in this presentation are those of the author and do not reflect the official policy of the Department of the Army, Department of Defense, or the U.S. Government. 17